Form 3 - Initial statement of beneficial ownership of securities
07 Septembre 2023 - 10:23PM
Edgar (US Regulatory)
Exhibit 24.1
LIMITED POWER OF ATTORNEY FOR SECTION 16
REPORTING OBLIGATIONS
Know all by these presents, that the undersigned
hereby makes, constitutes and appoints each of René Russo, Christopher Frankenfield, Kevin Brennan and Julia Walcott, signing singly
and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described
to:
(1) execute
for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Xilio Therapeutics, Inc. (the “Company”),
Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of
1934 and the rules thereunder (the “Exchange Act”);
(2) do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute
any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form
with the United States Securities and Exchange Commission and any stock exchange or similar authority;
(3) seek
or obtain, as the undersigned’s representative and on the
undersigned’s behalf, information regarding transactions in the
Company’s securities from any third party, including brokers, employee
benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such
attorney-in-fact and approves and ratifies any such release of information; and
(4) take
any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.
The
undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done
by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact,
in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving,
any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither
the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s
responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply
with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of
the Exchange Act.
This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing
attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of this 5th day of September, 2023.
|
/s/ Katarina Luptakova |
|
Signature |
|
|
|
|
|
Katarina Luptakova |
|
Print Name |
Xilio Therapeutics (NASDAQ:XLO)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Xilio Therapeutics (NASDAQ:XLO)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025